E. Bogart

Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patients

Athanasios Kakkos, L. Bresson, Delphine Hudry et al. · European Journal of Surgical Oncology · 2016 · 42 citations

Medicine, Oncology, Surgery +16

Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery

Houssein El Hajj, Marie Vanseymortier, Delphine Hudry et al. · ESMO Open · 2021 · 29 citations · Full text

Medicine, Oncology, Surgery +15

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)

Antoine Adenis, Jaafar Bennouna, Pierre-Luc Etienne et al. · European Journal of Cancer · 2019 · 23 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

How to report toxicity associated with targeted therapies?

Bastien Cabarrou, Jean‐Marie Boher, E. Bogart et al. · Annals of Oncology · 2016 · 14 citations

Pharmacy, Oncology, Pharmacology +12